NCI Experimental Therapeutics-Clinical Trials Network with Phase 1 Emphasis (ET-CTN) (UM1)

Post Date

February 8th 2013

Application Due Date

August 23rd 2013

Funding Opportunity Number

RFA-CA-13-006

CFDA Number(s)

93.395

Funding Instrument Type(s)

Cooperative Agreement

Funding Activity Categories

Education
Health

Number of Awards

10

Eligibility Categories

State Governments
Public and State Controlled Institutions of Higher Education
Non-Profits With 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Non-Profits Without 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Private Institutions of Higher Education
For-Profit Organizations (Except Small Businesses)
Small Businesses
Other

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Non-domestic (non-U.S.) Entities (Foreign Organizations); Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply but only if they are based in Canada. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply except for Canadian components. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Funding

• Estimated Total Funding:

  $8500000

• Award Range:

  $None - $850000

Grant Description

The purpose of this Funding Opportunity Announcement (FOA) issued by the National Cancer Institute (NCI) is to support an experimental therapeutics clinical trials program through the creation of a consolidated, integrated NCI Experimental Therapeutics-Clinical Trials Network (ET-CTN). This FOA solicits UM1 cooperative agreement applications for multidisciplinary groups that will conduct early phase experimental therapeutics clinical trials. Members of the ET-CTN will work on investigational agent-specific trans-network project teams to define the drug development plan, and to conduct experimental therapeutic clinical trials filed to the Investigational New Drug (IND) applications by NCIs Division of Cancer Treatment and Diagnosis (DCTD), Cancer Therapy Evaluation Program (CTEP).

Contact Information

• Agency

  Department of Health and Human Services

• Office:

  National Institutes of Health

• Agency Contact:

  NIH OER Webmaster
  FBOWebmaster@OD.NIH.GOV
  

• Agency Mailing Address:

  If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

• Agency Email Address:

  FBOWebmaster@OD.NIH.GOV

• More Information:

  http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-13-006.html